12 Month Price Forecast For ADGI
Distance to ADGI Price Forecasts
ADGI Price Momentum
🤔 Considering Adagio Therapeutics (ADGI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 4:55 PM UTC
ADGI Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for ADGI (Adagio Therapeutics).
ADGI is currently trading at $0.41. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADGI Analyst Consensus
ADGI Price Target Range
Latest ADGI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADGI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 16, 2022 | Morgan Stanley | Underweight | Maintains | $0.00 | |
| Sep 14, 2022 | Morgan Stanley | Underweight | Initiates | $0.00 | |
| May 17, 2022 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $3.00 |
| Jan 6, 2022 | Morgan Stanley | Matthew Harrison | Underweight | Downgrade | $6.00 |
| Dec 22, 2021 | Jefferies | Hold | Downgrade | $10.00 | |
| Dec 15, 2021 | Stifel | Stephen Willey | Hold | Downgrade | $9.00 |
| Dec 15, 2021 | Guggenheim | Neutral | Downgrade | $0.00 | |
| Dec 15, 2021 | Morgan Stanley | Matthew Harrison | Equal-Weight | Downgrade | $11.00 |
| Nov 29, 2021 | Morgan Stanley | Overweight | Upgrade | $0.00 | |
| Aug 31, 2021 | Guggenheim | Buy | Initiates | $0.00 | |
| Aug 31, 2021 | Stifel | Buy | Initiates | $0.00 | |
| Aug 31, 2021 | Jefferies | Buy | Initiates | $0.00 | |
| Aug 31, 2021 | Morgan Stanley | Equal-Weight | Initiates | $0.00 |
Stocks Similar to Adagio Therapeutics, Inc.
The following stocks are similar to Adagio Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adagio Therapeutics, Inc. (ADGI) Financial Data
Adagio Therapeutics, Inc. has a market capitalization of $17.33M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +77.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Adagio Therapeutics, Inc. (ADGI) Company Overview
About Adagio Therapeutics, Inc.
Company Information
Adagio Therapeutics, Inc. (ADGI) Latest News & Analysis
Rosen Law Firm reminds Invivyd, Inc. (formerly Adagio Therapeutics) investors of a lead plaintiff deadline on April 3, 2023, for potential compensation claims from the Class Period.
The deadline for lead plaintiff status in a securities class action can impact stock value, investor sentiment, and potential payouts for affected shareholders, influencing trading decisions.
Rosen Law Firm alerts Invivyd, Inc. (NASDAQ: IVVD) investors that the deadline to file as lead plaintiff for securities from Nov 29 to Dec 14, 2021, is April 3, 2023. No fees are required upfront.
The announcement signals potential legal action for Invivyd investors, indicating a chance for compensation, which could impact stock valuation and investor sentiment.
Rosen Law Firm alerts investors who bought Invivyd, Inc. securities between Nov 29 and Dec 14, 2021, of an April 3, 2023, lead plaintiff deadline for potential compensation claims.
The deadline for lead plaintiffs in the Invivyd securities case indicates potential legal liabilities and compensation opportunities, influencing investor sentiment and stock performance.
Rosen Law Firm alerts investors of Invivyd, Inc. (NASDAQ: IVVD) securities purchased between Nov 29, 2021, and Dec 14, 2021, of an April 3, 2023 lead plaintiff deadline for potential compensation.
The announcement highlights a legal opportunity for investors in Invivyd, potentially leading to compensation for losses incurred, which could affect stock sentiment and future trading activity.
Rosen Law Firm alerts Invivyd, Inc. (NASDAQ: IVVD) investors from Nov 29 to Dec 14, 2021, of an April 3, 2023 lead plaintiff deadline for potential compensation claims.
The deadline for filing claims could lead to increased volatility in Invivyd's stock, affecting its price and attracting attention from potential investors.
Rosen Law Firm alerts Invivyd, Inc. investors (NASDAQ: IVVD) from November 29 to December 14, 2021, about an April 3, 2023, lead plaintiff deadline for securities claims.
The announcement indicates a potential legal action involving Invivyd, which could impact stock performance, investor sentiment, and financial liability for the company.
Frequently Asked Questions About ADGI Stock
What is Adagio Therapeutics, Inc.'s (ADGI) stock forecast for 2025?
Analyst forecasts for Adagio Therapeutics, Inc. (ADGI) are not currently available. The stock is trading at $0.41.
Is ADGI stock a good investment in 2025?
Analyst ratings for ADGI are not currently available. The stock is currently trading at $0.41. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ADGI stock?
Price predictions from Wall Street analysts for ADGI are not currently available. The stock is trading at $0.41.
What is Adagio Therapeutics, Inc.'s business model?
N/A
What is the highest forecasted price for ADGI Adagio Therapeutics, Inc.?
Price targets from Wall Street analysts for ADGI are not currently available. The stock is trading at $0.41.
What is the lowest forecasted price for ADGI Adagio Therapeutics, Inc.?
Price targets from Wall Street analysts for ADGI are not currently available. The stock is trading at $0.41.
What is the overall ADGI consensus from analysts for Adagio Therapeutics, Inc.?
Analyst ratings for ADGI are not currently available. The stock is trading at $0.41.
How accurate are ADGI stock price projections?
Stock price projections, including those for Adagio Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
